{"nctId":"NCT00330681","briefTitle":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","startDateStruct":{"date":"2006-05"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"count":206,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-186"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of MCI-186"]}],"interventions":[{"name":"MCI-186","otherNames":["Edaravone","Radicut"]},{"name":"Placebo of MCI-186","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are defined as \"definite ALS,\" \"probable ALS\" or \"probable-laboratory-supported ALS,\" met diagnostic criteria revised EL Escorial for Airlie House.\n* Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.\n* Patients of less than 3 years after the onset of ALS.\n* Patients whose progress of the condition during 12 weeks before administration meet other requirements.\n\nExclusion Criteria:\n\n* Patients judged to be inadequate to participate in this study by their physician, because those patients' general condition deteriorated to the point that they need to be hospitalized for severe hepatic disease, severe heart disease, severe renal disease and so on, or they need to be administered antibiotics to infection.\n* Patients who complain the difficulty in breathing caused by deteriorating the respiratory function.\n* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.\n* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.\n* Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.\n* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","description":"ALSFRS-R Score: 0=worst; 48=best","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"0.85"},{"groupId":"OG001","value":"-6.35","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Death or a Specified State of Disease Progression","description":"Any of \"death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding\" was defined as an event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.57","spread":"2.41"},{"groupId":"OG001","value":"-17.49","spread":"2.39"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks","description":"The Modified Norris Scale is a measure of movement disorder for patients with ALS. Worst=0, Best=102","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.12","spread":"2.05"},{"groupId":"OG001","value":"-16.15","spread":"2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks","description":"The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, ADL and independence, eating and drinking, communication, and emotional reactions. Worst=200, Best=40","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"3.82"},{"groupId":"OG001","value":"19.13","spread":"3.79"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2","spread":null},{"groupId":"OG001","value":"88.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Drug Reactions","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Abnormal Changes in Sensory Examinations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":102},"commonTop":["Nasopharyngitis","Gait disturbance","Constipation","Insomnia","Contusion"]}}}